NCT02346253View on ClinicalTrials.gov

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

January 13, 2015

Primary Completion Date

December 14, 2021

Study Completion Date

May 17, 2026

Conditions
Prostate AdenocarcinomaStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer
Interventions
RADIATION

Internal Radiation Therapy

Undergo high-dose-rate brachytherapy

DRUG

Bicalutamide

Given PO

DRUG

Leuprolide Acetate

Given IM or SC

DRUG

Goserelin Acetate

Given SC

DRUG

Triptorelin Pamoate

Given IM

DRUG

Degarelix

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER